November 23, 2017 5:50 PM ET


Company Overview of Altor BioScience Corporation

Company Overview

Altor BioScience Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of immunotherapeutic agents for the treatment of cancer, viral infections, and inflammatory and autoimmune diseases. Its product candidates include ALT-801, a T-cell receptor-targeted immunotherapeutic for cancer; ALT-836, a monoclonal antibody-based tissue factor antagonist treatment of patients with acute respiratory distress syndrome and acute lung injury; and ALT-803, an IL-15 superagonist for patients with solid and hematological tumors/metastatic melanoma. The company’s product candidates also include ALT-802, a p53-TCR (T-cell receptors)/IgG1 fusion protein for treat...

2810 North Commerce Parkway

Miramar, FL 33025-3958

United States

Founded in 2002





Key Executives for Altor BioScience Corporation

Founder, Chief Executive Officer, President and Director
Chief Financial Officer
Age: 52
Vice Chairman and Chief Business Officer
Age: 68
Vice President of Research and Development
Consulting Medical Director and Member of Clinical Advisory Board
Compensation as of Fiscal Year 2017.

Altor BioScience Corporation Key Developments

Oxis International Inc. Enter Co-Development Partnership Agreement with Altor Bioscience Corp

Oxis International Inc. announced that it has entered into a co-development partnership agreement with Altor BioScience Corp. (Altor) in which the companies will collaborate exclusively in the clinical development of a novel 161533 TriKE fusion protein for cancer therapies using Oxis' trispecific killer engager (TriKE) technology. Under the partnership, Oxis and Altor will conduct a first-in-man Phase 1 FDA human clinical trial of the 161533 TriKE for the treatment of hematologic malignancies.

Altor Bioscience Corporation Announces FDA Fast Track Designation for Lead Candidate ALT-803 in Patients with Non-Muscle Invasive Bladder Cancer

Altor BioScience Corporation announced that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its investigational interleukin-15 (IL-15) agonist complex, ALT-803, in combination with bacillus Calmette-Guérin (BCG), for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). The FDA’s Fast Track program is designed to expedite the development and review of drugs to treat serious conditions and fill unmet medical needs. ALT-803 is currently being evaluated in a Phase Ib/II clinical trial to investigate the safety and efficacy of intravesical ALT-803 in combination with BCG in adult patients with BCG-naïve NMIBC as well as a separate Phase II clinical trial to investigate the safety and efficacy of intravesical ALT-803 in combination with BCG in adult patients with BCG-unresponsive NMIBC. Results from the recently completed Phase Ib NMIBC study will be presented at the American Urological Association Annual Meeting in Boston on May 12, 2017. The FDA Fast Track designation will apply to clinical development of ALT-803 in combination with BCG for the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder, as well as for the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR) in patients with NMIBC.

Altor BioScience Corporation Presents at BioFlorida Conference Jacksonville 2016, Dec-11-2016

Altor BioScience Corporation Presents at BioFlorida Conference Jacksonville 2016, Dec-11-2016 . Venue: Hyatt Regency Jacksonville Riverfront, 225 E Coastline Dr., Jacksonville, FL 32202, United States. Speakers: Warren Marcus, Business Development/Scientist.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

June 27, 2017
Private Placement
March 8, 2017

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Altor BioScience Corporation, please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at